Arcturus Therapeutics (ARCT) vs Opus Genetics (IRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Opus Genetics is the larger company by market cap ($366.9 million vs $362.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ARCT | IRD |
|---|---|---|
| Share price | $12.77 | $4.41 |
| Market cap | $362.82M | $366.89M |
| 1-day change | -1.81% | +0.68% |
| EPS (TTM) | $-3.33 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.17 | $7.07 |
| 52-week low | $5.50 | $1.70 |
| Distance from 52-week high | -47.19% | -37.62% |
| Average volume | 938.70K | 2.35M |
| Shares outstanding | 28.42M | 83.20M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ARCT vs IRD FAQ
Which is bigger, Arcturus Therapeutics or Opus Genetics?
Opus Genetics (IRD) is larger, with a market capitalization of $366.89M compared with $362.82M for Arcturus Therapeutics (ARCT).
Are Arcturus Therapeutics and Opus Genetics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.